Guggenheim Boosts Inventiva (NASDAQ:IVA) Price Target to $13.00

Key Points

• Guggenheim raised its price target for Inventiva from $9.00 to $13.00, reflecting a potential upside of 110.02% from the current stock price.
• Piper Sandler has also initiated coverage with an "overweight" rating and a price objective of $26.00, indicating strong confidence in the stock's performance.
• Inventiva, a clinical-stage biopharmaceutical company, is focused on developing therapies for diseases like non-alcoholic steatohepatitis and has its lead product, Lanifibranor, in Phase III trials.

Inventiva (NASDAQ:IVA - Get Free Report) had its price objective increased by equities research analysts at Guggenheim from $9.00 to $13.00 in a research note issued to investors on Tuesday, Marketbeat reports. The brokerage currently has a "buy" rating on the stock. Guggenheim's price objective indicates a potential upside of 133.39% from the company's previous close.

Separately, Piper Sandler began coverage on Inventiva in a research report on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 price target on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $14.83.

Inventiva Stock Down 0.5%

IVA stock traded down $0.03 during trading hours on Tuesday, hitting $5.57. 69,149 shares of the stock were exchanged, compared to its average volume of 67,695. The company has a 50-day simple moving average of $3.90 and a two-hundred day simple moving average of $3.46. Inventiva has a 12 month low of $1.53 and a 12 month high of $6.50.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Inventiva stock. Wealth Enhancement Advisory Services LLC grew its position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) by 54.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,558 shares of the company's stock after purchasing an additional 5,843 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Inventiva were worth $50,000 as of its most recent SEC filing. 19.06% of the stock is owned by hedge funds and other institutional investors.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.